Ardent Health Partners (NYSE:ARDT) Stock Price Expected to Rise, Leerink Partners Analyst Says

Ardent Health Partners (NYSE:ARDT) had its price objective raised by Leerink Partners from $23.00 to $25.00 in a research note released on Tuesday morning,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Several other analysts also recently weighed in on ARDT. Bank of America downgraded Ardent Health Partners from a “buy” rating to a “neutral” rating and cut their target price for the company from $22.00 to $19.00 in a research note on Wednesday, November 6th. Loop Capital initiated coverage on Ardent Health Partners in a research report on Monday, August 12th. They set a “buy” rating and a $18.00 target price on the stock. Morgan Stanley started coverage on Ardent Health Partners in a research report on Monday, August 12th. They set an “overweight” rating and a $27.00 price target on the stock. Citigroup started coverage on Ardent Health Partners in a research report on Monday, August 12th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $24.00 target price on shares of Ardent Health Partners in a research report on Thursday, September 19th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $21.82.

Ardent Health Partners Trading Down 2.8 %

Shares of NYSE ARDT traded down $0.50 during mid-day trading on Tuesday, hitting $17.31. The company had a trading volume of 14,792 shares, compared to its average volume of 369,450. Ardent Health Partners has a 12 month low of $14.57 and a 12 month high of $20.72. The company has a current ratio of 1.91, a quick ratio of 1.78 and a debt-to-equity ratio of 0.78. The firm’s 50 day simple moving average is $18.27.

Ardent Health Partners (NYSE:ARDT) last announced its quarterly earnings results on Wednesday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.05. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.46 billion. Equities research analysts expect that Ardent Health Partners will post 1.25 EPS for the current year.

Institutional Trading of Ardent Health Partners

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in Ardent Health Partners during the third quarter worth approximately $42,000. Financial Management Professionals Inc. bought a new stake in shares of Ardent Health Partners during the third quarter worth approximately $50,000. MetLife Investment Management LLC bought a new stake in shares of Ardent Health Partners during the third quarter worth approximately $135,000. Centiva Capital LP bought a new stake in shares of Ardent Health Partners during the third quarter worth approximately $469,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Ardent Health Partners during the third quarter worth approximately $526,000.

About Ardent Health Partners

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.